

# World Journal of *Methodology*

*World J Methodol* 2012 October 26; 2(5): 33-41





## Editorial Board

2011-2015

The *World Journal of Methodology* Editorial Board consists of 238 members, representing a team of worldwide experts in methodology. They are from 41 countries, including Argentina (2), Australia (7), Austria (3), Belgium (4), Brazil (3), Canada (10), China (27), Croatia (1), Cuba (1), Czech (3), Denmark (2), Egypt (1), France (6), Germany (4), Greece (3), Hungary (2), India (8), Iran (3), Israel (1), Italy (18), Japan (12), Lithuania (1), Malaysia (1), Mexico (2), Netherlands (2), New Zealand (1), Norway (3), Pakistan (2), Poland (2), Portugal (3), Romania (4), Russia (2), South Korea (3), Spain (17), Sweden (1), Thailand (2), Turkey (2), United Arab Emirates (1), United Kingdom (10), United States (57), and Uruguay (1).

### EDITOR-IN-CHIEF

Yicheng Ni, *Leuven*

### STRATEGY ASSOCIATE

#### EDITORS-IN-CHIEF

Guido Gainotti, *Rome*

Val J GebSKI, *Sydney*

Bo Hang, *Berkeley*

George A Kelley, *Morgantown*

Sang-Soo Lee, *Chuncheon*

Gerhard Litscher, *Graz*

Laurentiu M Popescu, *Bucharest*

António Vaz Carneiro, *Lisboa*

### GUEST EDITORIAL BOARD MEMBERS

Wen-Hsiung Chan, *Chung Li*

Long-Sen Chang, *Kaohsiung*

Hung-Jen Liu, *Taichung*

Ko-Huang Lue, *Taichung*

Chin-Tsan Wang, *I Lan*

Yau-Huei Wei, *Taipei*

Ching-Feng Weng, *Hualien*

### MEMBERS OF THE EDITORIAL BOARD



#### Argentina

Paula Abate, *Córdoba*

Rodolfo G Wuilloud, *Mendoza*



#### Australia

Felix Acker, *Melbourne*

Seetal Dodd, *Geelong*

Guy D Eslick, *Sydney*

Adrian J Gibbs, *Canberra*

Phillipa Jane Hay, *Sydney*  
Sanjay Patole, *Perth*



#### Austria

Gerwin A Bernhardt, *Graz*

Martin Voracek, *Vienna*



#### Belgium

Zeger Debyser, *Leuven*

Kristien Hens, *Leuven*

Piet K Vanhoenacker, *Aalst*



#### Brazil

Monica L Andersen, *Sao Paulo*

Mariana de Andrea Hacker, *Rio de Janeiro*

Moacyr A Rebello, *Rio de Janeiro*



#### Canada

Ahmed M Abou-Setta, *Edmonton*

Amir Azarpazhooh, *Toronto*

Elijah Dixon, *Calgary*

Martin A Katzman, *Toronto*

Alejandro Lazo-Langner, *London*

Richard WJ Neufeld, *London*

Prakesh S Shah, *Toronto*

Léon C van Kempen, *Montreal*

Yuzhuo Wang, *Vancouver*

Haishan Zeng, *Vancouver*



#### China

Deng-Feng Cao, *Beijing*

George G Chen, *Hong Kong*

William CS Cho, *Hong Kong*

Meng-Jie Dong, *Hangzhou*

Hani El-Nezami, *Hong Kong*

Rajiv Kumar Jha, *Xi'an*

Huang-Xian Ju, *Nanjing*

Yun-Feng Lin, *Chengdu*

Wing-Yee Lui, *Hong Kong*

Feng-Ming Luo, *Chengdu*

Jing-Yun Ma, *Beijing*

Hong-Xiang Sun, *Hangzhou*

Shi-Ying Xuan, *Qingdao*

Xilin Yang, *Hong Kong*

Bang-Ce Ye, *Shanghai*

Yue-Hong Zhang, *Hangzhou*

Zhongtying Zhao, *Hong Kong*

Chun-Fu Zheng, *Wuhan*

Ma Zheng, *Beijing*

Jun-Jie Zhu, *Nanjing*



#### Croatia

Marijeta Kralj, *Zagreb*



#### Cuba

Mariano R Ricard, *Habana*



#### Czech

Kamil Kuca, *Hradec Kralove*

Jiri Sedy, *Prague*

Miroslav Sip, *Ceske Budejovice*



#### Denmark

Morten Mørup, *Lyngby*

Hans Sanderson, *Roskilde*



**Egypt**

Nervana S Bayoumi, *Cairo*



**France**

Marc Y Bardou, *Dijon*  
Mohammed M Bettahar, *Nancy*  
Olivier David, *Grenoble*  
Florian Lesage, *Sophia Antipolis*  
Patrick Maison, *Creteil*  
Sandrine Marquet, *Marseille*



**Germany**

Harald Hampel, *Frankfurt/ Main*  
Frank Peinemann, *Cologne*  
M Lienhard Schmitz, *Giessen*  
Alfons Schnitzler, *Duesseldorf*



**Greece**

Konstantinos P Economopoulos, *Athens*  
Demosthenes Panagiotakos, *Athens*  
Issidora Papassideri, *Athens*



**Hungary**

Péter Halász, *Budapest*  
András Komócsi, *Pécs*



**India**

Dipshikha Chakravorty, *Bangalore*  
DK Dhawan, *Chandigarh*  
R Jayakumar, *Cochin*  
Abdul Viqar Khan, *Aligarh*  
Geetha Manivasagam, *Vellore*  
Jacob Peedicayil, *Vellore*  
YS Prabhakar, *Lucknow*  
Rakesh Kumar Sinha, *Ranchi*



**Iran**

Mehran Javanbakht, *Tehran*  
Enayat Kalantar, *Sanandaj*  
Shekoufeh Nikfar, *Tehran*



**Israel**

Dan Frenkel, *Tel Aviv*



**Italy**

Giuseppe Biondi-Zoccai, *Modena*  
Carlo Bonanno, *Vicenza*  
Paolo Borriero, *Turin*  
Filippo Cademartiri, *Monastier di Treviso*

Alberto Chiesa, *Bologna*  
Annamaria Cimini, *L'Aquila*  
Giovanni Di Leo, *San Donato Milanese*  
Giovanna Ferraioli, *Milan*  
Irene Floriani, *Milan*  
Landoni Giovanni, *Milano*  
Stefano Girotti, *Bologna*  
Paola Irato, *Padova*  
Mario Mascalchi, *Florence*  
Patrizia Mecocci, *Perugia*  
Germano Orrù, *Cagliari*  
Carlo Riccardi, *Perugia*  
Mauro Valtieri, *Rome*



**Japan**

Kohei Akazawa, *Niigata*  
Subash CB Gopinath, *Tsukuba*  
Koichi Hattori, *Tokyo*  
Satoshi Hirohata, *Okayama*  
Masahiro Kohzuki, *Sendai*  
Yoshinori Marunaka, *Kyoto*  
Kenji Miura, *Tokorozawa*  
Ryuichi Morishita, *Suita*  
Mitsuhiko Noda, *Tokyo*  
Yurai Okaji, *Tokyo*  
Hirosato Seki, *Osaka*  
Hisanori Umehara, *Kahoku-gun*



**Lithuania**

Giedrius Barauskas, *Kaunas*



**Malaysia**

Iis Sopyan, *Kuala Lumpur*



**Mexico**

Martha Rodríguez-Moran, *Durango*  
Julio Sotelo, *Mexico*



**Netherlands**

Bart J Polder, *Emmeloord*  
Frank Twisk, *Limmen*



**New Zealand**

Valery Feigin, *Auckland*



**Norway**

Cato Grønnerød, *Fredrikstad*  
David F Mota, *Oslo*  
Tore Syversen, *Trondheim*



**Pakistan**

Muhammad A Noor, *Islamabad*  
Yasir Waheed, *Islamabad*



**Poland**

Piotr Dziegiel, *Wroclaw*  
Tadeusz Robak, *Lodz*



**Portugal**

Nuno Lunet, *Porto*  
Hugo Sousa, *Porto*



**Romania**

Elena Moldoveanu, *Bucharest*  
Monica Neagu, *Bucharest*  
Florin-Dan Popescu, *Bucharest*



**Russia**

Galina B Bolshakova, *Moscow*  
Sergey V Dorozhkin, *Moscow*



**South Korea**

Sang Soo Hah, *Seoul*  
Chang-Yong Lee, *Kongju*



**Spain**

Salvador F Aliño, *Valencia*  
Mohamed Farouk Allam, *Cordoba*  
Alejandro Cifuentes, *Madrid*  
Miren Lopez de Alda, *Barcelona*  
Joaquin de Haro, *Madrid*  
Emma Garcia-Meca, *Cartagena*  
Mónica H Giménez, *Zaragoza*  
M de la Guardia, *Valencia*  
Josep M Guerrero, *Barcelona*  
Fernando Marin, *Madrid*  
José A Orosa, *A Coruña*  
Jesús Osada, *Zaragoza*  
Soledad Rubio, *Córdoba*  
Helmut Schröder, *Barcelona*  
Jesus Simal-Gandara, *Ourense*  
Gabriela Topa, *Madrid*  
Miguel A Vallejo, *Madrid*



**Sweden**

Jenny Selander, *Stockholm*



**Thailand**

Amporn Jariyapongsul, *Bangkok*  
Bungorn Sripanidkulchai, *Khon Kaen*



**Turkey**

Ferda E Percin, *Ankara*  
Aysegul Yildiz, *Izmir*



### United Arab Emirates

Hassib Narchi, *Al Ain*



### United Kingdom

Richard H Barton, *London*

Paul Evans, *London*

Giuseppe Garcea, *Leicester*

Sinead Keeney, *Belfast*

Maurice J O'Kane, *Londonderry*

Abdullah Pandor, *Sheffield*

Susan Pang, *Teddington*

Pankaj Sharma, *London*

David E Whitworth, *Aberystwyth*

Shangming Zhou, *Swansea*



### United States

Nasar U Ahmed, *Miami*

Mike Allen, *Milwaukee*

Srinivas Ayyadevara, *Little Rock*

Charles F Babbs, *West Lafayette*

Janet Barletta, *Baltimore*

Lawrence T Bish, *Philadelphia*

Richard W Bohannon, *Storrs*

Mark Bounthavong, *San Diego*

M Ahmad Chaudhry, *Burlington*

Pei Chen, *Beltsville*

Tao Chen, *Jefferson*

Yong Q Chen, *Winston-Salem*

Undurti N Das, *Shaker Heights*

Feng Ding, *Chapel Hill*

D Mark Estes, *Athens*

Bingliang Fang, *Houston*

Ronnie Fass, *Tucson*

Vesna D Garovic, *Rochester*

Alexandros Georgakilas, *Greenville*

Ronald Gillam, *Logan*

GAN Gowda, *West Lafayette*

James P Hardwick, *Rootstown*

Diane M Harper, *Kansas*

Odette A Harris, *Stanford*

Rod Havriluk, *Tallahassee*

Moonseong Heo, *Bronx*

Guoyuan Huang, *Evansville*

Reinhold J Hutz, *Milwaukee*

Bankole A Johnson, *Charlottesville*

Jennifer Kisamore, *Tulsa*

Georgios D Kitsios, *Boston*

Heidemarie Kremer, *Miami*

Dawei Li, *New Haven*

JL Mehta, *Little Rock*

Ray M Merrill, *Provo*

M Mimeault, *Nebraska*

Ron B Mitchell, *St Louis*

Yan Peng, *Dallas*

George Perry, *San Antonio*

Ilona Petrikovics, *Huntsville*

Shengping Qin, *Davis*

Peter J Quesenberry, *Providence*

P Hemachandra Reddy, *Beaverton*

Paul R Sanberg, *Tampa*

Dong-Chul Seo, *Bloomington*

Weihong Tan, *Gainesville*

Guangwen Tang, *Boston*

Catherine E Ulbricht, *Somerville*

Thomas TH Wan, *Orlando*

Xiao-Jing Wang, *Aurora*

Jang-Yen Wu, *Boca Raton*

Qing Wu, *Scottsdale*

Eleftherios S Xenos, *Lexington*

Xinan Yang, *Chicago*

Henry Zeringue, *Pittsburgh*



### Uruguay

Matias Victoria, *Salto*



### ORIGINAL ARTICLE

33

LC-MS/MS analysis of 2-aminothiazoline-4-carboxylic acid as a forensic biomarker for cyanide poisoning

*Yu JCC, Martin S, Nasr J, Stafford K, Thompson D, Petrikovics I*

## Contents

*World Journal of Methodology*  
Volume 2 Number 5 October 26, 2012

**ACKNOWLEDGMENTS** I Acknowledgments to reviewers of *World Journal of Methodology*

**APPENDIX** I Meetings  
I-V Instructions to authors

**ABOUT COVER** *World Journal of Methodology* Editorial Board, Srinivas Ayyadevara, Research Health Scientist, Research Assistant Professor, Department of Geriatrics, University of Arkansas for Medical Sciences, John L McClellan Medical Center, 4300 West 7th Street, Research 151, Room GB 103, Little Rock, AR 72205, United States

**AIM AND SCOPE** *World Journal of Methodology* (*World J Methodol*, *WJM*, online ISSN 2222-0682, DOI: 10.5662) is a bimonthly peer-reviewed, online, open-access (OA), journal supported by an editorial board consisting of 23 experts in methodology from 41 countries.

*WJM* aims to rapidly report the most recent results in medical diagnostics, therapeutic techniques and equipment, clinical medical research, clinical and experimental techniques and methodology. It provides a platform to facilitate the integration of clinical medicine and experimental techniques and methodology to help clinicians improve diagnostic accuracy and therapeutic efficacy. The journal publishes original articles and reviews on the following topics: (1) Clinical medical techniques, including but not limited to those for pharmaceutical medicine, laboratory medicine, radioactive medicine, medical imaging, nuclear medicine, physical therapy, pathology, surgery, disinfection, nutritional therapy, transfusion and medical equipment; (2) Clinical medical research on etiology, epidemiology, pathogenesis, morphology and function, signs and symptoms, clinical trials, and evidence-based medicine; and (3) Laboratory methodology, including but not limited to techniques in DNA/RNA sequencing, preparation and transformation of competent cells, PCR, protein biochemistry, cell biology, genetics and epigenetics, immunology, microbiology, animal models of human pathologies, bioinformatics, and laboratory equipment manipulation and control.

**FLYLEAF** I-III Editorial Board

## EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Yuan Zhou*  
Responsible Electronic Editor: *Xiao-Mei Zheng*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Jin-Lei Wang*  
Proofing Editorial Office Director: *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Methodology*

**ISSN**  
ISSN 2222-0682 (online)

**LAUNCH DATE**  
September 26, 2011

**FREQUENCY**  
Bimonthly

**EDITING**  
Editorial Board of *World Journal of Methodology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: [wjm@wjgnet.com](mailto:wjm@wjgnet.com)  
<http://www.wjgnet.com>

**EDITOR-IN-CHIEF**  
Yicheng Ni, MD, PhD, Professor, Department of

Radiology, University Hospitals, KU, Leuven, Herestraat 49, B-3000, Leuven, Belgium

**EDITORIAL OFFICE**  
Jian-Xia Cheng, Director  
Jin-Lei Wang, Vice Director  
*World Journal of Methodology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: [wjm@wjgnet.com](mailto:wjm@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Co., Limited  
Room 1701, 17/F, Henan Building,  
No.90 Jaffe Road, Wanchai,  
Hong Kong, China  
Fax: +852-31158812  
Telephone: +852-58042046  
E-mail: [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
October 26, 2012

**COPYRIGHT**  
© 2012 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at [http://www.wjgnet.com/2222-0682/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2222-0682/g_info_20100722180909.htm)

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/esp/>



## LC-MS/MS analysis of 2-aminothiazoline-4-carboxylic acid as a forensic biomarker for cyanide poisoning

Jorn CC Yu, Sarah Martin, Jessica Nasr, Katelyn Stafford, David Thompson, Ilona Petrikovics

Jorn CC Yu, Sarah Martin, Department of Forensic Science, College of Criminal Justice, Sam Houston State University, Huntsville, TX 77341, United States

Jessica Nasr, Katelyn Stafford, David Thompson, Ilona Petrikovics, Department of Chemistry, Sam Houston State University, Huntsville, TX 77341, United States

**Author contributions:** Martin S, Nasr J and Stafford K performed the majority of experiments; Thompson D was involved in editing the manuscript and in scientific discussions; Yu JCC and Petrikovics I designed the study and wrote the manuscript.

**Supported by** NIH: NIAID/USAMRICD Interagency Agreements (W911NF-07-D-0001) and the USAMRICD under the auspices of the US Army Research Office Scientific Services Program administered by Battelle (Delivery order 0557, Contract No TCN 08284), and the Robert A. Welch Foundation at Sam Houston State University, Huntsville, TX, United States

**Correspondence to:** Ilona Petrikovics, PhD, Associate Professor, Department of Chemistry, Sam Houston State University, Huntsville, TX 77341, United States. [ixp004@shsu.edu](mailto:ixp004@shsu.edu)  
Telephone: +1-936-2944389 Fax: +1-936-2944996

Received: February 4, 2012 Revised: August 10, 2012

Accepted: September 6, 2012

Published online: October 26, 2012

**RESULTS:** A custom made analytical method was established for a new (mice) model when animals were exposed to increasing KCN doses. The application of this method provided important new information on ATCA as a potential cyanide biomarker. ATCA concentration in mice plasma samples were increased from  $189 \pm 28$  ng/mL ( $n = 3$ ) to  $413 \pm 66$  ng/mL ( $n = 3$ ) following a 10 mg/kg body weight dose of KCN introduced subcutaneously. The sensitivity of this analytical method proved to be a tool for measuring endogenous level of ATCA in mice organs as follows:  $1.2 \pm 0.1$  µg/g for kidney samples,  $1.6 \pm 0.1$  µg/g for brain samples,  $1.8 \pm 0.2$  µg/g for lung samples,  $2.9 \pm 0.1$  µg/g for heart samples, and  $3.6 \pm 0.9$  µg/g for liver samples.

**CONCLUSION:** This finding suggests that ATCA has the potential to serve as a plasma biomarker / forensic biomarker for cyanide poisoning.

© 2012 Baishideng. All rights reserved.

**Key words:** Forensic science; Biomarker; Cyanide poisoning; 2-aminothiazoline-4-carboxylic acid; LC-MS/MS

**Peer reviewers:** Srinivas Ayyadevara, Research Health Scientist, Research Assistant Professor, Department of Geriatrics, University of Arkansas for Medical Sciences, John L McClellan Medical Center, 4300 West 7th Street, Research 151, Room GB 103, Little Rock, AR 72205, United States; Murielle Mimeault, PhD, Department of Biochemistry and Molecular Biology, College of Medicine, Eppley Cancer Institute, 7052 DRC, University of Nebraska Medical Center, 985870 Nebraska Medical Center, Omaha, NE 68198-5870, United States; Soledad Rubio, Professor, Department of Analytical Chemistry, University of Córdoba, Edificio Anexo Marie Curie, Campus de Rabanales, 14017, Córdoba, Spain

Yu JCC, Martin S, Nasr J, Stafford K, Thompson D, Petrikovics I. LC-MS/MS analysis of 2-aminothiazoline-4-carboxylic acid as a forensic biomarker for cyanide poisoning. *World J Methodol* 2012; 2(5): 33-41 Available from: URL: <http://www.wjgnet.com/2222-0682/full/v2/i5/33.htm> DOI: <http://dx.doi.org/10.5662/wjm.v2.i5.33>

### Abstract

**AIM:** To demonstrate the potential of using 2-aminothiazoline-4-carboxylic acid (ATCA) as a novel biomarker/ forensic biomarker for cyanide poisoning.

**METHODS:** A sensitive method was developed and employed for the identification and quantification of ATCA in biological samples, where the sample extraction and clean up were achieved by solid phase extraction (SPE). After optimization of SPE procedures, ATCA was analyzed by high performance liquid chromatography-tandem mass spectrometry. ATCA levels following the administration of different doses of potassium cyanide (KCN) to mice were measured and compared to endogenous ATCA levels in order to study the significance of using ATCA as a biomarker for cyanide poisoning.

## INTRODUCTION

Cyanide is a swift and powerful poison. Suicidal, accidental, or homicidal death involving the determination of cyanide is encountered frequently in forensic toxicological practice<sup>[1]</sup>. In crime scene investigations, two indicators of acute cyanide poisoning are (1) a “bitter almond” odor emanating from the victim; and (2) the presence of pink lividity in the post mortem examination<sup>[2]</sup>. The presence of cyanide can be confirmed chemically using a colorimetric test at the scene of the crime, followed by a laboratory analysis using a gas chromatography-mass spectrometry (GC-MS). Samples, such as stomach contents and whole blood are usually collected from victims and analyzed in order to confirm the cause of death<sup>[3]</sup>. The determination of the presence of cyanide involves extraction of hydrogen cyanide (HCN) from samples and the measurement of cyanide from the extracts<sup>[4,5]</sup>. Biological fluids, such as blood or urine can be taken from the subject for analysis<sup>[6-9]</sup>. Due to the relatively short half-life of cyanide (from minutes to hours depending on the matrix), direct analysis of cyanide to confirm cyanide poisoning may only be feasible within the first few hours following exposure<sup>[10-12]</sup>.

Natural dietary and pulmonary intake of cyanide from the environment provides a nonzero cyanide background level in the body. Smoke inhalation in fires greatly increases background cyanide levels<sup>[13]</sup>. The volatility and reactivity of cyanide leaves direct measurements highly susceptible to errors introduced during the sample collection and separation step<sup>[14]</sup>. An alternative approach that can help to minimize false positive (no cyanide is involved but cyanide is detected) and false negative (cyanide is involved but cyanide is not detected) results, is to detect stable biomarkers of cyanide, rather than cyanide itself. Thiocyanate (SCN<sup>-</sup>), 2-aminothiazoline-4-carboxylic acid (ATCA), and cyanide-protein adducts in biological fluids and tissues have been reported as alternative biomarkers for cyanide exposure and poisoning<sup>[15,16]</sup>. SCN<sup>-</sup> is the major cyanide metabolite found in blood<sup>[17]</sup>. However, SCN<sup>-</sup> is also a natural metabolite of non-cyanide mediated pathways and thus is not a good marker for cyanide exposure<sup>[18]</sup>.

Detoxification of cyanide by cystine to produce ATCA *in vivo* was first reported by Wood and Cooley<sup>[19]</sup>. They found that the pathway producing ATCA represents approximately 20% of cyanide metabolism, that the quantity of ATCA produced is directly proportional to the amount of cyanide metabolized, and that harvested ATCA is stable for months in the freezer<sup>[20]</sup>. Therefore, ATCA has been considered a promising candidate as a chemically stable biomarker for cyanide poisoning. More details of human metabolism of cyanide and detection of its biomarkers can be found in a recent review published by Logue *et al.*<sup>[21]</sup>. Aside from the -cyanide mediated pathway, there are currently no other known pathway for endogenous ATCA production in the human body.

There are numerous analytical techniques to determine cyanide<sup>[22]</sup> and thiocyanate<sup>[23]</sup> or both<sup>[24,25]</sup> in biologi-

cal samples, but only a few techniques are available to measure ATCA. Quantitative analysis of ATCA begins with extraction from biological samples followed by derivatization to produce a sample that is suitable for quantitative analysis with liquid chromatography or gas chromatography. Cation exchange solid-phase extraction (SPE) columns and individual pre-treatment steps for the extraction and analysis of ATCA from biological samples have been reported<sup>[26,27]</sup>. Derivatization steps were needed in those studies due to the use of either fluorometric detection or gas chromatography. Molecularly imprinted stir bar sorption extraction (MISBSE) of ATCA was reported by Jackson *et al.*<sup>[28]</sup>. The MISBSE technique enables the selective extraction of ATCA from urine samples followed by direct detection of ATCA (without derivatization) by a tandem mass spectrometer. This technique may in the future provide rapid analytical method for the direct detection of ATCA for forensic urine analysis, but at the moment, MISBSE is not competitive with standard SPE methods due to the low binding capacities and sample recoveries.

The purpose of this study was to determine the optimal conditions for the quantification of ATCA in various biological fluids and organs using SPE, and high performance liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Conditions associated with SPE sample loading, washing and final elution, were studied and refined. The effect of ATCA signal fluctuations arising from electrospray ionization (ESI) suppression was minimized by using a structural analogue of ATCA (2-aminothiazole-4-carboxylic acid, ATZA) as an internal standard. Similar LC-MS/MS analysis was previously reported and employed for different purposes with different experimental setups on different animal (rat) models<sup>[29,30]</sup>. Determining ATCA levels in plasma and various organs after a constant dose of cyanide exposure [4 mg/kg potassium cyanide (KCN)] indicated that the plasma ATCA level following cyanide exposure was not significantly elevated from the endogenous ATCA level. This suggested that ATCA might not be a good biomarker for cyanide intoxication<sup>[29]</sup>; however, this study also demonstrated that ATCA is a valuable forensic biomarker, since the ATCA level significantly increased in certain organs after a constant dose (4 mg/kg) of KCN administration. To determine how long ATCA persists in the circulation, ATCA was injected to the bloodstream, and samples were taken at periodic time intervals, and analyzed by the LC-MS/MS method<sup>[30]</sup>. Results suggested that ATCA is a chemically stable metabolite, suitable as a forensic biomarker. This study also compared the two sample preparation methods of SPE and MISBSE suggesting the priority of SPE over MISBSE. Present studies are reporting ATCA levels after exposing mice to higher, increasing (6, 6, 8 and 10 mg/kg) KCN doses. Exogenously elevated levels of ATCA were compared to endogenous levels of ATCA present in the biological fluids and organs prior to challenge. This new method can be extended to future toxicokinetic studies of ATCA in other animal models in order to confirm the significance of using ATCA as a



biomarker from different biological matrices for human cyanide poisoning.

## MATERIALS AND METHODS

### Ethics


All animal procedures were conducted in accordance with the guidelines in The Guide for the Care and Use of Laboratory Animals (National Academic Press, 1996). The research facility was accredited by AAALAC (American Association for the Assessment and Accreditation of Laboratory Animal Care, International) and this animal study was approved by the IACUC (Institutional Animal Care and Use Committee) at Sam Houston State University.

### Chemicals and samples

Trifluoroacetic acid (TFA) was obtained from EMD Chemicals (Gibbstown, NJ, USA) and used to prepare 0.5% (v/v) TFA in methanol (0.5% TFA/MeOH) as the mobile phase. All solvents were at least HPLC grade. ATCA was obtained from Chem-Impex International (Wood Dale, IL, USA). ATZA was obtained from Synthonix (Wake Forest, NC, USA). Molecular structures of ATCA and ATZA are shown in Figure 1. KCN was purchased from Sigma-Aldrich (St. Louis, MO, USA). For *in vivo* study, serial dilutions were used to produce aqueous KCN solutions of systematically decreasing concentration. KCN is acutely toxic. Ingestion of KCN or exposure to its salt or its aqueous solutions by eye or skin contact can be fatal. Exposure to as little as 50-150 mg can cause immediate collapse and death. Working with cyanide-containing compounds requires special care. Oasis® mixed mode cation exchange (MCX) cartridges were obtained from Waters Corporation (Milford, MA, USA). A 5% aqueous ammonium hydroxide/methanol solution (v/v) was prepared and used as the final elution solution. Mice liver, plasma, brain, heart and lung were used to evaluate the applicability of the analytical method.

### Instrumentation

SPE was performed in a glass manifold equipped with Teflon needle inserts and evacuated with a Buchi V-700 Vacuum Pump (Mallinckrodt Baker, Inc., Phillipsburg, NJ, USA). Homogenization was performed with ready-to-use Precellys® lysing kits on a Precellys-24 tissue homogenizer (Bertin Technologies, France). Pierce Reacti-Therm II Heating Module was used to stream air to borosilicate glass disposable culture tubes (13 mm × 100 mm). A Shimadzu liquid chromatograph (LC-20AT, Shimadzu, Columbia, MD) coupled to a tandem mass spectrometer (API 3200 ESI/MS/MS system, Applied Biosystems, Foster City, CA) was employed for the LC-MS/MS separation, detection and quantification of ATCA. A Luna CN column (3 micron, 100 mm × 2 mm; Phenomenex; Torrance, CA, USA) was used for the separation. A 5 µL aliquot was injected to the LC-MS/MS by an auto-sampler, and eluted isocratically at a 0.5 mL/min flow



**Figure 1** Molecular structures of 2-aminothiazoline-4-carboxylic acid and 2-aminothiazole-4-carboxylic acid. 2-aminothiazole-4-carboxylic acid (ATZA) served as an internal standard. ATCA: 2-aminothiazoline-4-carboxylic acid.

rate. Transition ions of ATCA in positive mode ( $m/z$  147 → 101) and ATZA ( $m/z$  145 → 127) were generated using ESI and detected using multiple reaction monitoring (MRM). The source dependent conditions of ESI were as follows: ionspray voltage: +5500 V, temperature: 450 °C, curtain gas 350 kPa, gas 1: 480 kPa, gas 2: 140 kPa. The compound dependent parameters were as follows: collision gas (CAD): 41 kPa, collision cell entrance potential: 14 V, and the collision cell exit potential: 4 V. More instrumentation details of ESI/MS/MS for the detection of ATCA can be found in our previous report<sup>[24]</sup>.

### Sample preparation and SPE procedure

ATCA standard solutions with concentrations ranging from 0-1000 ng/mL, were prepared from 330 µg/mL ATCA standard stock solutions by serial dilutions. Internal standard, 10 µg/mL of ATZA, was prepared from a 282 µg/mL ATZA standard stock solution. Both ATCA and ATZA stock solutions were prepared in mobile phase (0.5% TFA/MeOH). To construct the calibration curve, 200 µL of each standard solution was mixed with 20 µL of internal standard. The standard solutions were sonicated for 5 min and then dried. They were reconstituted with 220 µL of mobile phase, and then a 5 µL aliquot was injected to the LC-MS/MS for analysis.

To prepare the ATCA spiked samples, known amounts of ATCA were air-dried in the test tubes. Two hundred microliters of sample (urine, plasma, and organ homogenates) and 20 µL internal standard were added to these test tubes and diluted with 800 µL of 10 mmol/L phosphate buffer (pH 7.4) before SPE. For organ homogenization, samples were thawed, chopped, and weighed in homogenizing tubes, and 0.1 mol/L HCl was added to make a concentration of 0.6 g organ mass/mL in each tube. The samples were homogenized for 3 min, 1 min per cycle with 3 cycles at 6000 r/min using the Precellys 24. Homogenized mixtures of samples were diluted with 10 mmol/L phosphate buffer (pH 7.4) to obtain a final concentration of organ homogenate of 0.15 g organ mass/mL buffer. The solution was vortexed and centrifuged for 10 min at 10 000 r/min and the supernatant was removed for the SPE extraction.

SPE was performed on a MCX cartridge prior to the LC-MS/MS analysis. The MCX cartridges were conditioned with 1 mL of methanol and then 1 mL of distilled water. The samples (1 mL total) were loaded into the conditioned

cartridges employing vacuum as needed. After sample loading, the cartridges were washed with 1 mL of 0.1 mol/L HCl first and then washed with 1 mL methanol. The cartridges were finally eluted with 1 mL of 5% (v/v) ammonium hydroxide in methanol (5% NH<sub>4</sub>OH/MeOH). Note that teflon inserts and waste test tubes were replaced with clean inserts and glass test tubes before final elution. The eluates were air dried first, then reconstituted with 220  $\mu$ L of mobile phase. After sonication for 5 min, the reconstituted samples were transferred to LC-MS/MS auto-sampler vials containing 250  $\mu$ L glass inserts.

### Quantitative analysis of ATCA

Detection of ATCA by ESI/MS/MS has been previously reported<sup>[24]</sup>. Briefly, 5  $\mu$ g/mL ATCA and ATZA standard solutions were infused separately to the MS/MS at 10  $\mu$ L/min in order to observe certain compound-dependent parameters for MRM transitions. When ATCA standard solution was infused to the ESI source under optimal ESI conditions, the ATCA molecular ion at  $m/z$  147, corresponding to (M + H)<sup>+</sup>, was detected. ATCA product ion at  $m/z$  101 was the most abundant product ion after the optimization of compound-dependent parameters of MRM, hence the transition ion  $m/z$  147  $\rightarrow$  101 was selected for identification and quantification of ATCA. Similarly, ATZA molecular ion at  $m/z$  145 was generated under the optimal ESI condition. Its product ion  $m/z$  127 was the most abundant product ions after optimization of compound-dependent parameters of MRM, hence the transition ion  $m/z$  145  $\rightarrow$  127 was selected for detection of the internal standard (ATZA). An internal standard corrected calibration curve was constructed by plotting the ratio of ATCA peak area to ATZA peak area *vs* ATCA concentrations. External calibration curves were also constructed to examine matrix and ionization suppression effects.

### Quality control

The quality control (QC) sample was a 200  $\mu$ L, 500 ng/mL ATCA standard with 20  $\mu$ L of 10  $\mu$ g/mL internal standard. The QC was analyzed prior to each sample to ensure that the instrumentation was working properly. Additionally, a blank sample (mobile phase with the internal standard only) was also run between samples to check for any potential carryovers. The peak shape for the QC was confirmed first, and any deviation from the known peak shape was interpreted as an instrumentation error. Conditioning of separation column and tubing was performed when high backpressure was noticed. Once QC was passed, samples were analyzed using LC-MS/MS with good confidence.

### Animal studies

For animal studies, Charles River provided the 18 CD-1 mice, all of which were male and weighed about 20 g. The experimental animals were housed in room temperature and light controlled rooms (22  $^{\circ}$ C  $\pm$  2  $^{\circ}$ C, 12-h light/dark cycle). They were furnished with water and Teklad Rodent


Diet (W) 8604 (Teklad HSD, Inc., WI, USA) ad libitum. Plasma and organs (brain, lungs, heart, liver, and kidneys) of the mice were collected after subcutaneous injection of KCN at different doses. Three sublethal doses (6, 8, and 10 mg/kg-body-weight) were applied (3 mice/dose), and the injection solutions were prepared from a 4-mg/mL KCN stock solution. Each dose was injected with a 25 G  $\times$  1 1/2 needle. Mice were terminated 15 min after cyanide exposure and organs were collected. Blood samples were taken by pipetting. The average volume of blood obtained was 0.25 mL, and the blood was placed into Eppendorf tubes with 40  $\mu$ L of 10 mg/mL of heparin in water. The Eppendorf tubes were vortexed, then centrifuged at 13 000 r/min for 5 min. Plasma was collected, and organs were collected as well. Plasma and organ samples were placed into plastic 3 mL tubes and stored in the freezer until they were thawed for analysis. Note that longer exposure of cyanide was not performed in this work. The toxicokinetic and half-life studies of ATCA are separate research projects in our laboratory.

## RESULTS

### SPE procedure

The use of MCX cartridge for the extraction of ATCA from acidified urine samples has been previously reported<sup>[20]</sup>. The ATCA was eluted from the cartridge by concentrated NH<sub>4</sub>OH and converted to the trimethylsilyl derivative through reaction with 30% N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) in hexane before analysis by GC-MS. In our work, we have modified and optimized the SPE procedure for LC-MS/MS instrumentation. ATCA was detected by ESI-MS/MS without chemical derivatization. The impact of solvent composition on ATCA and ATZA ionization at the ESI source was tested first. Solvents of three ATCA standard solutions (500 ng/mL with ATZA) were evaporated by air (air-dry) and argon (argon-dry) gases and the residues were reconstituted with a freshly prepared mobile phase. As shown in Figure 2, the MS/MS signals of ATCA and ATZA were compared with and without air drying. The decreased peak areas of ATCA and ATZA in reconstituted solutions following air or argon drying were attributed to the variations of TFA concentration in the stock solution and the freshly prepared mobile phase. Solvent evaporation with argon had similar effects to that with air. Therefore, the use of an inert gas was not needed for solvent evaporation. It has been known that TFA is a good organic additive in chromatography, but a poor reagent for MS/MS signal. In our method development, it was unfortunate that we could not avoid the need for evaporation of samples and calibration standards.

Concentrated (28%-30%) aqueous ammonium hydroxide, 5% NH<sub>4</sub>OH/MeOH, 0.5% TFA/MeOH, and 1% TFA/MeOH were next tested to determine the optimal final elution solution. Triplicates of each solution were performed through SPE. The optimal final elution solution was also determined by using 2 different elution



**Figure 2** Comparison of 2-aminothiazoline-4-carboxylic acid and 2-aminothiazole-4-carboxylic acid signals detected by LC-MS/MS before and after evaporation of solvents by air or argon stream. The decreased peak areas of 2-aminothiazoline-4-carboxylic acid (ATCA) and 2-aminothiazole-4-carboxylic acid (ATZA) in reconstituted solutions following air or argon drying were attributed to the variations of trifluoroacetic acid concentration in the stock solution and the freshly prepared mobile phase. Solvent evaporation with argon had similar effects to that with air. Therefore, the use of an inert gas was not needed for solvent evaporation.


volumes (1 and 2 mL) of 5%  $\text{NH}_4\text{OH}/\text{MeOH}$ . Triplicates of each volume were performed through SPE. These solutions yielded similar recoveries of ATCA and ATZA. Because 5%  $\text{NH}_4\text{OH}/\text{MeOH}$  was relative easy to air-dry, it was selected as the final elution solution for SPE.

#### Optimal SPE procedure for ATCA extraction

Various SPE procedures were tested and the best recovery was obtained using the procedure below. Mice plasma or homogenized mice organs (200  $\mu\text{L}$ ) mixed with 20  $\mu\text{L}$  of internal standard (ATZA) was diluted with 800  $\mu\text{L}$  of 10 mmol/L phosphate buffer (pH 7.4). ATCA and ATZA were then extracted with and eluted from the MCX cartridge. The samples eluted by the final elution solution were dried under gentle air streams. After air drying, the residues were reconstituted with 220  $\mu\text{L}$  of mobile phase. Standard solutions and samples were then sonicated for 5 min prior to LC-MS/MS analysis. With a volatile organic additive, such as TFA, in the mobile phase, it is challenging to keep its concentration a constant from batch to batch. A precise control of TFA concentration, or elimination of matrix components could be investigated for method development, however, it is more applicable to just use an internal standard for calibration in our method.

#### Use of TFA as an additive in mobile phase

In our previous studies using ESI/MS/MS, a mobile phase of 0.5% acetic acid gave a good yield of the MRM transition ion of  $m/z$  147  $\rightarrow$  101 for the detection of ATCA. This mobile phase was found to be a poor eluent of ATZA. However, as shown in Figure 3, when TFA was added to the mobile phase a good sharp ATZA peak was detected. This result suggested that TFA was a




**Figure 3** Comparison of chromatograms of 2-aminothiazoline-4-carboxylic acid and 2-aminothiazole-4-carboxylic acid obtained by using 0.5% acetic acid/MeOH as mobile phase (A and C) and 0.5% trifluoroacetic acid/MeOH as mobile phases (B and D). When trifluoroacetic acid (TFA) was added to the mobile phase a good sharp 2-aminothiazole-4-carboxylic acid (ATZA) peak was detected. This result suggested that TFA was a more effective ion-pairing reagent than acetic acid during the chromatography. Therefore, 0.5% TFA/MeOH was selected as the mobile phase, replacing the 0.5% acetic acid/MeOH mobile phase used in our prior work. ATCA: 2-aminothiazoline-4-carboxylic acid.

more effective ion-pairing reagent than acetic acid during the chromatography. Therefore, 0.5% TFA/MeOH was selected as the mobile phase, replacing the 0.5% acetic acid/MeOH mobile phase used in our prior work.


#### Use of ATZA as the internal standard

ATCA standard solutions, ranging from 0-1000 ng/mL, were analyzed by LC-MS/MS with ATZA as the internal standard. External calibration curves were first constructed to show the relationship between ATCA concentrations and integrated ATCA LC-MS/MS peak areas. As shown in Figure 4A, the external standard calibration curves showed good linearity over the tested ATCA concentration range with average  $R^2 = 0.999$  in a between-days experiment. The dashed lines show linear regression of calibration in each day. These linear regression lines yielded an average calibration equation  $y = (199 \pm 60) \times (n = 4)$ , relative standard deviation (RSD) of calibration slopes = 30%. The high %RSD of the slopes indicated a typical ionization suppression effect of ESI. Internal calibration curves were next prepared by plotting the ratio



**Figure 4** External calibration curves, without using 2-aminothiazole-4-carboxylic acid as the internal standard (A) and internal standard calibration curves constructed using 2-aminothiazole-4-carboxylic acid as the internal standard (B). A: The external standard calibration curves showed good linearity over the tested 2-aminothiazole-4-carboxylic acid (ATCA) concentration range with average  $R^2 = 0.999$  in a between-days experiment. The dashed lines show linear regression of calibration in each day. These linear regression lines yielded an average calibration equation  $y = (199 \pm 60) \times (n = 4)$ , relative standard deviation (RSD) of calibration slopes = 30%. The high %RSD of the slopes indicated a typical ionization suppression effect of electrospray ionization. Internal calibration curves were next prepared by plotting the ratio of ATCA to 2-aminothiazole-4-carboxylic acid (ATZA) peak areas vs ATCA concentration; B: Ratioing to the internal standard peak area improved the reproducibility of the calibration curves. The dashed lines show calibration curves obtained on different days. These internal standard compensated calibration curves yielded an average calibration equation  $y = (0.018 \pm 0.00007) \times (n = 4)$ , RSD = 4%. The decrease of the RSD from 30% (external calibration) to 4% (internal standard calibration) demonstrated that the internal standard, ATZA, enables effective compensation for ionization suppression and matrix effects, and substantially improves the precision with which ATCA can be quantified.

of ATCA to ATZA peak areas *vs* ATCA concentration. As shown in Figure 4B, ratioing to the internal standard peak area improved the reproducibility of the calibration curves. The dashed lines show calibration curves obtained on different days. These internal standard compensated calibration curves yielded an average calibration equation  $y = (0.018 \pm 0.00007) \times (n = 4)$ , RSD = 4%. The decrease of the RSD from 30% (external calibration) to 4% (internal standard calibration) demonstrated that the internal standard, ATZA, enables effective compensation for ionization suppression and matrix effects, and substantially improves the precision with which ATCA can be quantified. The effect of matrix components on MS/MS signals could be determined by comparing the



**Figure 5** Endogenous level of 2-aminothiazoline-4-carboxylic acid in mice organs. The endogenous levels of 2-aminothiazoline-4-carboxylic acid (ATCA) in different organs of mice were measured using the solid phase extraction procedure and LC-MS/MS conditions outlined above. Triplicate samples from healthy mice showed endogenous ATCA concentrations as follows:  $1.2 \pm 0.1$  μg/g for kidney samples,  $1.6 \pm 0.1$  μg/g for brain samples,  $1.8 \pm 0.2$  μg/g for lung samples,  $2.9 \pm 0.1$  μg/g for heart samples, and  $3.6 \pm 0.9$  μg/g for liver samples.

slope of internal standard calibration curves and matrix added calibration curves (e.g., standard addition). However, it could not eliminate matrix effect for the different biological samples. Note that the use of an internal standard does not mean that the method is interference-free.

### Endogenous level of ATCA in mice organs


The endogenous levels of ATCA in different organs of mice were measured using the SPE procedure and LC-MS/MS conditions outlined above. As showed in Figure 5, triplicate samples from healthy mice showed endogenous ATCA concentrations as follows:  $1.2 \pm 0.1$  μg/g for kidney samples,  $1.6 \pm 0.1$  μg/g for brain samples,  $1.8 \pm 0.2$  μg/g for lung samples,  $2.9 \pm 0.1$  μg/g for heart samples, and  $3.6 \pm 0.9$  μg/g for liver samples.

## DISCUSSION

Mobile phase composition can impact the ESI ionization of analytes<sup>[27]</sup>. The responses of positive ions may be varied by changes in the electrolyte concentration, pH, and percent methanol at the ESI ionization source<sup>[28]</sup>. TFA has been known to suppress ESI<sup>[29]</sup>. For quantitative analysis, it is important to air-dry the ATCA and ATZA standard solutions so that all solutions can be redissolved in the same batch of mobile phase (freshly prepare mobile phase is recommended). This ensures reproducible ionization suppression from sample to sample. We found that this solvent reconstitution step increased the precision of signal from replicate standard solutions (%RSD of ATCA < 5% and %RSD of ATZA < 8%). Note that the ring in ATCA may open under heat and basic conditions<sup>[24]</sup>. The evaporation of solvent should be performed under ambient temperature.

Matrix components in the sample could interfere with the detection of ATCA in LC-MS/MS. SPE was used to isolate the analyte from the complex sample matrices. However, while SPE generally reduces matrix effects, it can under certain circumstances also magnify matrix ef-





**Figure 6** 2-aminothiazoline-4-carboxylic acid concentration in mice plasma after different doses of potassium cyanide (endogenous level = 0 mg/kg body weight dose of potassium cyanide). Mice received three different sublethal doses (6, 8 and 10 mg/kg) of cyanide subcutaneously (3 mice/doses) and were terminated 15 min after cyanide exposure. A significant correlation of cyanide dose vs 2-aminothiazoline-4-carboxylic acid (ATCA) concentration in plasma samples was observed. ATCA concentration in mice plasma samples was increased from  $189 \pm 28$  ng/mL ( $n = 3$  mice) for endogenous level [0 mg/kg body weight dose of potassium cyanide (KCN)] to  $413 \pm 66$  ng/mL ( $n = 3$  mice) for 10 mg/kg body weight dose of KCN.

fects<sup>[30]</sup>, an internal standard was needed to minimize this deviation of calibration. Ideally, the choice of deuterated ATCA as the internal standard has advantages chromatographically and can eliminate limitations of chemical properties in separation and detection method development. Unfortunately, deuterated ATCA was not commercially available. From this work, ATZA was selected and proved as to be a good alternative as an internal standard. The use of ATZA as an internal standard successfully mitigated ESI suppression and matrix effects. Note that the difference in the chemical properties of ATZA and ATCA has been shown by the difference in MS/MS fragmentation and the pKa of ATZA is different from ATCA which potentially can be a problem in separation. Fortunately, ATZA co-eluted with ATCA in our method. This is advantageous because ion suppression at the ESI source should then be more uniform for both ATCA and ATZA.

It has been suggested in an *in vivo* study that the reaction of an oxidized disulfide with a sulfur nucleophile from glutathione could be a plausible origin for ATCA<sup>[27]</sup>. It is likely that endogenous levels of ATCA in each organ reflect the availability of disulfide and the concentration of glutathione in those organs. Thus, endogenous ATCA levels may give an estimate of each organ's capacity for cyanide detoxification. For example, the preliminary results showing lower endogenous ATCA levels in the kidneys and brain may be consistent with lower capacity for cyanide detoxification in those organs. This lower capacity might be partially due to the absence of rhodanese enzymes in the kidney and brain.

Mice received three different sublethal doses (6, 8 and 10 mg/kg) of cyanide subcutaneously (3 mice/doses) and were terminated 15 min after cyanide exposure. As shown in Figure 6, a significant correlation of cyanide dose vs ATCA concentration in plasma samples was observed. ATCA concentration in mice plasma samples was

increased from  $189 \pm 28$  ng/mL ( $n = 3$  mice) for endogenous level (0 mg/kg body weight dose of KCN) to  $413 \pm 66$  ng/mL ( $n = 3$  mice) for 10 mg/kg body weight dose of KCN. This data represents the first *in vivo* study of ATCA concentration levels in plasma samples following administration of various controlled doses of cyanide.

Present *in vivo* study confirmed that ATCA concentration in plasma samples rose significantly with increasing cyanide dose levels in a mice model. This finding suggests that ATCA has the potential to serve as a plasma biomarker for cyanide poisoning. However, further studies for detecting ATCA in biological samples after exposure of various cyanide doses employing various animal models are necessary to reaffirm that ATCA can be established as a suitable cyanide biomarker/forensic biomarker. Since it is previously proven that ATCA is a persistent, chemically stable metabolite<sup>[26]</sup>, more over the formed ATCA concentrations are significantly enhanced in certain organs even after a lower dose of cyanide exposure<sup>[25]</sup>. This method can also be readily applied to actual autopsy materials. It is important to develop this method into a complementary method to extend the detection time window for cyanide poisoning cases, especially for those autopsy samples that have been stored for a long time where cyanide poisoning was suspected. These studies are superior to the previously reported studies with a different animal model (rat)<sup>[25]</sup>. While the previous experimental setup of applying one single KCN dose (4 mg/kg) did not prove the potential importance of ATCA as a plasma biomarker, present studies confirm that at higher doses of KCN administration the plasma ATCA level is proportionally and significantly increasing with increasing KCN doses. Earlier studies indicated enhanced ATCA levels in the urine and plasma<sup>[20]</sup> of smokers vs non smokers, suggesting that ATCA has potential as a cyanide biomarker in human. Different cyanide metabolite baseline levels in smokers vs nonsmokers is a factor that needs to be accounted for in all methods, including ATCA based methods, that seek to differentiate between chronic and acute cyanide exposure. Present findings provide additional evidence to the study by Logue *et al.*<sup>[20]</sup>, for the potential of ATCA to serve as a plasma biomarker in mice and human, and confirm its utility as a forensic biomarker what was in agreement with the earlier investigation using a single lower dose of KCN in a rat model<sup>[29]</sup>.

## ACKNOWLEDGEMENTS

Research supports from the Faculty Enhancement Grants for Research from Sam Houston State University was greatly appreciated.

## COMMENTS

### Background

Cyanide (CN) is a potent poison, which people can be exposed to in a various ways. It has been widely recognized as a chemical warfare agent and is considered as a possible terrorist threat. It is important to determine cyanide itself, or its metabolites in biological matrices for forensic, clinical, military, research



and veterinary purposes. Common metabolites of cyanide include 2-aminothiazoline-4-carboxylic acid (ATCA) and thiocyanate. ATCA is formed when cyanide reacts with cysteine.

### Research frontiers

One of the most important frontiers in cyanide research to develop effective methods for forensic analysis of cyanide exposure, based on detection of CN and its metabolites (thiocyanate and ATCA). Since cyanide is present in the body in the volatile hydrogen cyanide form, it is rapidly depleted from blood (generally within the first 20 min of exposure) following exposure, leaving only metabolites as biomarkers. Important criteria for a biomarker include chemical stability, and biomarker concentration levels in biological matrices that correlate with the doses of exposure. Earlier studies proved that ATCA is a chemically stable cyanide metabolite. The present study indicates the cyanide dose vs ATCA blood concentration relation, therefore it suggests that ATCA might be established as a cyanide biomarker.

### Innovations and breakthroughs

Logue *et al* (2005 and 2010) reported an analytical method gas chromatography-mass spectrometry (GC-MS) to measure ATCA in biological matrices. Since ATCA is not volatile, it requires derivatization prior to measurement via GC-MS. The authors' HPLC method detects ATCA without derivatization. For sample preparation before injecting the samples to the chromatography column (LC-MS/MS method), Yu's group at SHSU (Jackson *et al*, 2010) developed and reported a molecularly imprinted polymer stir bar sorption extraction for determining ATCA. The present study employs the LC-MS/MS method, and it compared the two extraction methods (molecularly imprinted polymer stir bar sorption extraction and SPE), and for further analysis it recommends the SPE extraction when determining ATCA by LC/MS/MS method. Employing the HPLC/MS/MS method with SPE extraction, this study confirmed that ATCA can serve as a biomarker for cyanide exposure. In an earlier study (Petrikovics *et al*, 2011) reported the possible establishment of ATCA as a forensic biomarker, since the post exposure concentration of ATCA in organs was significantly elevated relative to the endogenous ATCA levels, especially in the liver in a rat model. Further investigations are being pursued to determine endogenous cysteine/cystine levels in order to understand why certain organs contain more ATCA after a constant cyanide exposure. When a constant low dose of cyanide was administered, the plasma ATCA level was not elevated relative to the endogenous plasma ATCA. In the present study the authors report that when cyanide doses are higher, and more representative of acute exposure, the ATCA levels in the plasma are correlated with CN dose in a mice model.

### Applications

This results of this study suggest that ATCA holds promise as a forensic biomarker for CN.

### Peer review

The results of this study show that ATCA levels are strongly correlated with CN exposure levels in a mice model. These results are consistent with the hypothesis that ATCA might serve as a biomarker/ forensic biomarker for cyanide exposure.

## REFERENCES

- 1 Lv J, Zhang Z, Li J, Luo L. A micro-chemiluminescence determination of cyanide in whole blood. *Forensic Sci Int* 2005; **148**: 15-19
- 2 Gill JR, Marker E, Stajic M. Suicide by cyanide: 17 deaths. *J Forensic Sci* 2004; **49**: 826-828
- 3 Laforge M, Buneaux F, Houeto P, Bourgeois F, Bourdon R, Levillain P. A rapid spectrophotometric blood cyanide determination applicable to emergency toxicology. *J Anal Toxicol* 1994; **18**: 173-175
- 4 Darr RW, Capson TL, Hileman FD. Determination of hydrogen cyanide in blood using gas chromatography with alkali thermionic detection. *Anal Chem* 1980; **52**: 1379-1381
- 5 Shiono H, Maseda C, Akane A, Matsubara K. Rapid and sensitive quantitation of cyanide in blood and its application to fire victims. *Am J Forensic Med Pathol* 1991; **12**: 50-53
- 6 McAuley F, Reive DS. Rapid quantitation of cyanide in blood by gas chromatography. *J Anal Toxicol* 1983; **7**: 213-215
- 7 Ishii A, Seno H, Watanabe-Suzuki K, Suzuki O, Kumazawa T. Determination of cyanide in whole blood by capillary gas chromatography with cryogenic oven trapping. *Anal Chem* 1998; **70**: 4873-4876
- 8 Zamecnik J, Tam J. Cyanide in blood by gas chromatography with NP detector and acetonitrile as internal standard. Application on air accident fire victims. *J Anal Toxicol* 1987; **11**: 47-48
- 9 Lundquist P, Rammer L, Sörbo B. The role of hydrogen cyanide and carbon monoxide in fire casualties: a prospective study. *Forensic Sci Int* 1989; **43**: 9-14
- 10 Moriya F, Hashimoto Y. Potential for error when assessing blood cyanide concentrations in fire victims. *J Forensic Sci* 2001; **46**: 1421-1425
- 11 Calafat AM, Stanfill SB. Rapid quantitation of cyanide in whole blood by automated headspace gas chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci* 2002; **772**: 131-137
- 12 McAllister JL, Roby RJ, Levine B, Purser D. Stability of cyanide in cadavers and in postmortem stored tissue specimens: a review. *J Anal Toxicol* 2008; **32**: 612-620
- 13 Noguchi TT, Eng JJ, Klatt EC. Significance of cyanide in medicolegal investigations involving fires. *Am J Forensic Med Pathol* 1988; **9**: 304-309
- 14 Lindsay AE, Greenbaum AR, O'Hare D. Analytical techniques for cyanide in blood and published blood cyanide concentrations from healthy subjects and fire victims. *Anal Chim Acta* 2004; **511**: 185-195
- 15 Baskin SI, Petrikovics I, Platoff GE, Rockwood GA, Logue BA. Spectrophotometric Analysis of the Cyanide Metabolite 2-Aminothiazoline-4-Carboxylic Acid (ATCA). *Toxicol Mech Methods* 2006; **16**: 339-345
- 16 Isom GE, Baskin SI. Enzymes involved in cyanide metabolism. In: Sipes IG, McQueen CA, Gandolfi AJ, editors. *Comprehensive Toxicology*. New York: Elsevier Science, 1997: 477-488
- 17 Baskin SI, Petrikovics I, Kurche JS, Nicholson JD, Logue BA, Maliner BJ, Rockwood GA. Insights on Cyanide Toxicity and Methods of Treatment. In: Flora SJS, Romano JA, Baskin SI, Sekhar K, editors. *Pharmacological perspectives of toxic chemicals and their antidotes*. New Delhi: Narosa Publishing House, 2004: 105-146
- 18 Ballantyne B. In vitro production of cyanide in normal human blood and the influence of thiocyanate and storage temperature. *Clin Toxicol* 1977; **11**: 173-193
- 19 Wood JL, Cooley SL. Detoxication of cyanide by cystine. *J Biol Chem* 1956; **218**: 449-457
- 20 Logue BA, Kirschten NP, Petrikovics I, Moser MA, Rockwood GA, Baskin SI. Determination of the cyanide metabolite 2-aminothiazoline-4-carboxylic acid in urine and plasma by gas chromatography-mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2005; **819**: 237-244
- 21 Logue BA, Hinkens DM, Baskin SI, Rockwood GA. The analysis of cyanide and its breakdown products in biological samples. *Crit Rev Anal Chem* 2010; **40**: 122-147
- 22 Youso SL, Rockwood GA, Lee JP, Logue BA. Determination of cyanide exposure by gas chromatography-mass spectrometry analysis of cyanide-exposed plasma proteins. *Anal Chim Acta* 2010; **677**: 24-28
- 23 Youso SL, Rockwood GA, Logue BA. The analysis of protein-bound thiocyanate in plasma of smokers and non-smokers as a marker of cyanide exposure. *J Anal Toxicol* 2012; **36**: 265-269
- 24 Kage S, Nagata T, Kudo K. Determination of cyanide and thiocyanate in blood by gas chromatography and gas chromatography-mass spectrometry. *J Chromatogr B Biomed Appl* 1996; **675**: 27-32
- 25 Tsuge K, Kataoka M, Seto Y. Cyanide and thiocyanate levels in blood and saliva of healthy adult volunteers. *J Health Sci* 2000; **46**: 343-350
- 26 Bradham LS, Catsimpoalas N, Wood JL. Determination of 2-iminothiazolidine-4-carboxylic acid. *Anal Biochem* 1965; **11**: 230-237
- 27 Lundquist P, Kagedal B, Nilsson L, Rosling H. Analysis of

- the cyanide metabolite 2-aminothiazoline-4-carboxylic acid in urine by high-performance liquid chromatography. *Anal Biochem* 1995; **228**: 27-34
- 28 **Jackson R**, Petrikovics I, Lai EPC, Yu JCC. Molecularly imprinted polymer stir bar sorption extraction and electrospray ionization tandem mass spectrometry for determination of 2-aminothiazoline-4-carboxylic acid as a marker for cyanide exposure in forensic urine analysis. *Anal Method* 2010; **2**: 552-557
  - 29 **Petrikovics I**, Thompson DE, Rockwood GA, Logue BA, Martin S, Jayanna P, Yu JCC. Organ-distribution of the metabolite 2-aminothiazoline-4-carboxylic acid in a rat model following cyanide exposure. *Biomarkers* 2011; **16**: 686-690
  - 30 **Petrikovics I**, Yu JCC, Thompson DE, Jayanna P, Logue BA, Nasr J, Bhandari RK, Baskin SI, Rockwood G. Plasma persistence of 2-aminothiazoline-4-carboxylic acid in rat system determined by liquid chromatography tandem mass spectrometry. *J Chromatog B* 2012; **891-892**: 81-84

S- Editor Jiang L L- Editor A E- Editor Zheng XM

## Acknowledgments to reviewers of *World Journal of Methodology*

We acknowledge our sincere thanks to our reviewers. Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of our World Series Journals. Both the editors of the journals and authors of the manuscripts submitted to the journals are grateful to the following reviewers for reviewing the articles (either published or rejected) over the past period of time.

**Richard W Bohannon, EdD, DPT, Professor**, Kinesiology, University of Connecticut, 358 Mansfield Road, Storrs, CT 06269, United States

**Sang-Soo Lee, MD, PhD, Professor**, Head of Orthopedic Surgery, Chief Planning Officer, Institute for Skeletal Aging and Orthopedic Surgery, Chunchon Sacred Heart Hospital-Hallym University, 153 Gyodong, Chunchonsi, Kangwondo 200-704, South Korea

**Wen-Hsiung Chan, PhD, Professor**, Department of Bioscience Technology, Chung Yuan Christian University, No. 200, Chung Pei Road, Chung Li 32023, Taiwan, China

**András Komócsi, MD, PhD**, Heart Centre, University of Pécs, 13. Ifjúság, Pécs H-7621, Hungary

**Rodolfo G Wuilloud, PhD**, Analytical Chemistry Research and Development Group, LISAMEN – CCT – CONICET – Mendoza, Av. Ruiz Leal S/N Parque General San Martín, M 5502 IRA Mendoza, Argentina

**Mariana de Andrea Hacker, PhD**, Laboratory of Leprosy, Oswaldo Cruz Foundation, Avenida Brasil 4365 –Manguinhos, Rio de Janeiro 21040360, Brazil

**Richard WJ Neufeld, PhD, Professor**, Department of Psychology, University of Western Ontario, Westminster Hall, London, Ontario N6B 2K3, Canada

**William CS Cho, PhD, FHKIMLS, Chartered Scientist (UK), FHKSMDS, FIBMS (UK), Consultant of Registered Chinese Medicine Practitioner Association**, Department of Clinical Oncology, Queen Elizabeth Hospital, Room 1305, 13/F, Block R, 30 Gascoigne Road, Kowloon, Hong Kong, China

**Hong-Xiang Sun, PhD, Associate Professor**, College of Animal Sciences, Zhejiang University, Yuhangtang Road 866, Hangzhou 310053, Zhejiang Province, China

**Marijeta Kralj, PhD, Senior Scientist, Head** of Laboratory of Experimental Therapy, Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb 10000, Croatia

**Peter J Quesenberry, MD**, Division of Hematology, Oncology, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, United States

**Thomas TH Wan, PhD, MHS, Professor and Associate Dean** for Research, College of Health and Public Affairs, PO Box 163680, Orlando, FL 32826-3680, United States

## Events Calendar 2012

January 20-21, 2012

AGA Clinical Congress of Gastroenterology and Hepatology: Practice, Evidence and Quality in 2012  
Miami, FL, United States

January 26, 2012

Symposium of the Swiss Society of Pharmacology and Toxicology, Advances in Pharmacology - Cardiovascular Pharmacology  
Bern, Switzerland

January 28 - February 1, 2012

LabAutomation2012  
Palm Springs Convention Center,  
Palm Springs, CA, United States

February 1-4, 2012

3rd International Workshop on Medical Image Analysis and Description for Diagnosis System  
Hotel Tivoli Victoria, Algarve, Portugal

February 24, 2012

State Stem Cell Agency Governance Subcommittee  
San Francisco, CA, United States

March 11-14, 2012

Thoracic Imaging 2012  
Hyatt Regency, Huntington Beach Resort and Spa, Huntington Beach, CA, United States

March 25-30, 2012

44th International Diagnostic Course

Davos (IDKD)

Davos, Switzerland

April 26-29, 2012

75th Anniversary of the Canadian Association of Radiologists Annual Scientific Meeting  
Le Centre Sheraton, Montreal, Quebec, Canada

April 29 - May 4, 2012

EUCHEM Conference on Stereochemistry  
Brunnen, Switzerland

May 4-6, 2012

World Congress on Biotechnology  
Hyderabad, India

June 7-9, 2012

ASCI 2012 - 6th Congress of Asian Society of Cardiovascular Imaging  
Bangkok, Thailand

June 9-13, 2012

2012 Annual Meeting of the Society of Nuclear Medicine  
Miami Beach, FL, United States

August 15-19, 2012

ICE 2012 - International Congress of Endoscopy  
Daegu, South Korea

October 28-30, 2012

EANM 2012 - Annual Congress of the European Association of Nuclear Medicine  
Milan, Italy

## GENERAL INFORMATION

*World Journal of Methodology* (World J Methodol, WJM, online ISSN 2222-0682, DOI: 10.5662) is a bimonthly peer-reviewed, online, open-access (OA), journal supported by an editorial board consisting of 238 experts in methodology from 41 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

### Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of WJM and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since WJM is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from WJM official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality ar-

ticles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

### Aims and scope

WJM aims to rapidly report the most recent results in medical diagnostics, therapeutic techniques and equipment, clinical medical research, clinical and experimental techniques and methodology. It provides a platform to facilitate the integration of clinical medicine and experimental techniques and methodology to help clinicians improve diagnostic accuracy and therapeutic efficacy. The journal publishes original articles and reviews on the following topics: (1) Clinical medical techniques, including but not limited to those for pharmaceutical medicine, laboratory medicine, radioactive medicine, medical imaging, nuclear medicine, physical therapy, pathology, surgery, disinfection, nutritional therapy, transfusion and medical equipment; (2) Clinical medical research on etiology, epidemiology, pathogenesis, morphology and function, signs and symptoms, clinical trials, and evidence-based medicine; and (3) Laboratory methodology, including but not limited to techniques in DNA/RNA sequencing, preparation and transformation of competent cells, PCR, protein biochemistry, cell biology, genetics and epigenetics, immunology, microbiology, animal models of human pathologies, bioinformatics, and laboratory equipment manipulation and control.

### Columns

The columns in the issues of WJM will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide Guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in basic and clinical medical research methodology; (9) Brief Articles: To briefly report the novel and innovative findings in basic and clinical medical research methodology; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in WJM, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of basic and clinical medical research methodology; (13) Guidelines: To introduce Consensuses and Guidelines reached by international and national academic authorities worldwide on the research basic and clinical medical research methodology; and (14) Voices: to publicize methodology-related communications that have been rejected or impossible for publication elsewhere due to evident prejudice and/or unreasonable reasons. Similarly, your experiences of the proven mistreatment during the past grant applications can be narrated or documented in this corner. The corresponding responses and echoes from readers are also welcome here.



## Instructions to authors

### Name of journal

*World Journal of Methodology*

### ISSN

ISSN 2222-0682 (online)

### Editor-in-Chief

**Yicheng Ni, MD, PhD, Professor**, Department of Radiology, University Hospitals, KU, Leuven, Herestraat 49, B-3000, Leuven, Belgium

### Editorial Office

*World Journal of Methodology*

Editorial Department: Room 903, Building D,

Ocean International Center,

No. 62 Dongsihuan Zhonglu,

Chaoyang District, Beijing 100025, China

E-mail: [wjm@wjgnet.com](mailto:wjm@wjgnet.com)

<http://www.wjgnet.com>

Telephone: +86-10-85381891

Fax: +86-10-85381893

### Indexed and Abstracted in

Digital Object Identifier.

### Published by

Baishideng Publishing Group Co., Limited

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJM* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS

([http://www.wjgnet.com/2222-0682/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2222-0682/g_info_20100722180909.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjm@wjgnet.com](mailto:wjm@wjgnet.com), or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. [montgomery.bissell@ucsf.edu](mailto:montgomery.bissell@ucsf.edu)

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which

were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJM*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

### Abstract

There are unstructured abstracts (no less than 256 words) and structured abstracts (no less than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no less than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no less than 140 words); RESULTS (no less than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ; CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725072755.htm](http://www.wjgnet.com/2222-0682/g_info_20100725072755.htm).

### Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...etc. It is our principle to publish high resolution-figures for the printed and E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any

## Instructions to authors

footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorheide AM. Adolescent pregnancy. 2nd ed. Wiecezorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1



**Statistical data**

Write as mean  $\pm$  SD or mean  $\pm$  SE.

**Statistical expression**

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

**Units**

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5  $\mu$ g/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725073806.htm](http://www.wjgnet.com/2222-0682/g_info_20100725073806.htm).

**Abbreviations**

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

**Italics**

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindIII*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

**Examples for paper writing**

**Editorial:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725071851.htm](http://www.wjgnet.com/2222-0682/g_info_20100725071851.htm)

**Frontier:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725071932.htm](http://www.wjgnet.com/2222-0682/g_info_20100725071932.htm)

**Topic highlight:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725072121.htm](http://www.wjgnet.com/2222-0682/g_info_20100725072121.htm)

**Observation:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725072232.htm](http://www.wjgnet.com/2222-0682/g_info_20100725072232.htm)

**Guidelines for basic research:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725072344.htm](http://www.wjgnet.com/2222-0682/g_info_20100725072344.htm)

**Guidelines for clinical practice:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725072543.htm](http://www.wjgnet.com/2222-0682/g_info_20100725072543.htm)

**Review:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725072656.htm](http://www.wjgnet.com/2222-0682/g_info_20100725072656.htm)

**Original articles:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725072755.htm](http://www.wjgnet.com/2222-0682/g_info_20100725072755.htm)

**Brief articles:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725072920.htm](http://www.wjgnet.com/2222-0682/g_info_20100725072920.htm)

**Case report:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725073015.htm](http://www.wjgnet.com/2222-0682/g_info_20100725073015.htm)

**Letters to the editor:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725073136.htm](http://www.wjgnet.com/2222-0682/g_info_20100725073136.htm)

**Book reviews:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725073214.htm](http://www.wjgnet.com/2222-0682/g_info_20100725073214.htm)

**Guidelines:** [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725073300.htm](http://www.wjgnet.com/2222-0682/g_info_20100725073300.htm)

**SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED**

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade B certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

**Language evaluation**

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

**Copyright assignment form**

Please download a Copyright assignment form from [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725073726.htm](http://www.wjgnet.com/2222-0682/g_info_20100725073726.htm).

**Responses to reviewers**

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/2222-0682/g\\_info\\_20100725073445.htm](http://www.wjgnet.com/2222-0682/g_info_20100725073445.htm).

**Proof of financial support**

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

**Links to documents related to the manuscript**

WJPM will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

**Science news releases**

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

**Publication fee**

WJPM is an international, peer-reviewed, OA, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. Editorial, topic highlights, book reviews and letters to the editor are published free of charge.